Preclinical Data Suggests Expanded Therapeutic
Potential of the Hemopurifier® Beyond Virology and Oncology
Results Support Further Evaluation of the
Hemopurifier® as Part of a Machine
Perfusion Circuit to Further Assess its Impact on the Function of
Retrieved Kidneys
SAN
DIEGO, March 10, 2025 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company
focused on developing products to treat cancer and life-threatening
infectious diseases and for use in organ transplantation, today
announced the publication of a pre-clinical study in the
peer-reviewed journal Transplant Immunology
(https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, " A lectin affinity
plasmapheresis device removes extracellular vesicles and microRNAs
from renal perfusates following controlled oxygenated rewarming of
discarded donor kidneys."
Aethlon Medical's Hemopurifier® is a therapeutic
blood filtration system designed to bind and remove harmful
extracellular vesicles and life-threatening viruses from blood and
other biological fluids. Its capabilities have potential
applications in oncology and infectious diseases, and organ
transplantation.
"Kidney transplantation provides the highest quality of life for
those afflicted with end stage renal disease, yet there is a
shortage of organs available, and for those who do receive organs,
complications may include delayed function and organ rejection,"
stated Steven LaRosa, MD, Senior
Author of the publication and Chief Medical Officer of Aethlon
Medical. "The use of machine perfusion of recovered organs as
opposed to cold storage has helped but there is still room for
improvement. The release of extracellular vesicles (EVs) and
microRNAs from the donor kidney are hypothesized to play a role in
these complications. With that in mind, we specifically examined
the ability of the Hemopurifier to remove EVs and noxious microRNAs
from the perfusion fluid from discarded kidneys that had undergone
Controlled Oxygenated Rewarming. We demonstrated significant
reductions in EVs as well as microRNAs implicated in renal
dysfunction."
"While the company's funding and focus are dedicated to the
Australian and India Oncology trials, the data generated from this
pre-clinical study demonstrates that extracellular vesicle removal
as a therapeutic target for the Hemopurifier extends beyond
virology and oncology. We believe there exists a "pipeline within a
device"," added James Frakes, Chief
Executive Officer and Chief Financial Officer of Aethlon Medical.
However, we acknowledge that further evaluation is needed,
including incorporating the Hemopurifier into a machine perfusion
circuit with discarded kidneys followed by a clinical trial. Our
technology could be potentially "bolted on" to existing organ
preservation technology.
About Aethlon and the
Hemopurifier®
Aethlon Medical is a medical
therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat
cancer and life-threatening viral infections and for use in organ
transplantation. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and in
pre-clinical studies, the Hemopurifier has demonstrated the removal
of harmful exosomes from biological fluids, utilizing its
proprietary lectin-based technology. This action has potential
applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious
diseases. The Hemopurifier is a U.S. Food and Drug Administration
(FDA) designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. The Hemopurifier also
holds an FDA Breakthrough Device designation and an open
Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found
at www.AethlonMedical.com.
Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that involve risks and uncertainties.
Statements containing words such as "may," "believe," "anticipate,"
"expect," "intend," "plan," "project," "will," "projections,"
"estimate," "potentially" or similar expressions constitute
forward-looking statements. Such forward-looking statements are
subject to significant risks and uncertainties and actual results
may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are
based upon Aethlon's current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Factors
that may contribute to such differences include, without
limitation, the Company's ability to raise additional capital and
to successfully complete development of the Hemopurifier; the
Company's ability to successfully demonstrate the utility of the
Hemopurifier in removing EVs and microRNAs from renal perfusates;
the Company's ability to conduct its planned oncology clinical
trials in Australia and
India; the Company's ability to
manage and successfully complete its current and future clinical
trials, if initiated; the Company's ability to conduct clinical
trial(s) designed to demonstrate benefits of the incorporation of
the Hemopurifier® into renal
perfusion; the Company's ability to successfully manufacture the
Hemopurifier in sufficient quantities for its clinical trials, and
other potential risks. The foregoing list of risks and
uncertainties is illustrative, but is not exhaustive. Additional
factors that could cause results to differ materially from those
anticipated in forward-looking statements can be found under the
caption "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended March 31, 2024,
and in the Company's other filings with the Securities and Exchange
Commission, including its quarterly Reports on Form 10-Q. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except as may be
required by law, the Company does not intend, nor does it undertake
any duty, to update this information to reflect future events or
circumstances.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-publishes-preclinical-data-on-the-hemopurifier-in-transplant-immunology-journal-302396250.html
SOURCE Aethlon Medical, Inc.
